vs
Civeo Corp（CVEO）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
Civeo Corp的季度营收约是再鼎医药的1.3倍（$161.6M vs $127.1M），再鼎医药同比增速更快（17.1% vs 7.1%），Civeo Corp自由现金流更多（$14.5M vs $-26.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs -1.4%）
希维欧公司（Civeo Corporation）是一家美国住宿服务跨国企业，从石油国家国际公司（Oil States International）拆分而来，目前是在纽约证券交易所挂牌上市的公众公司，主要为能源等行业项目提供人员住宿配套服务解决方案。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
CVEO vs ZLAB — 直观对比
营收规模更大
CVEO
是对方的1.3倍
$127.1M
营收增速更快
ZLAB
高出10.0%
7.1%
自由现金流更多
CVEO
多$41.2M
$-26.7M
两年增速更快
ZLAB
近两年复合增速
-1.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $161.6M | $127.1M |
| 净利润 | $-6.5M | — |
| 毛利率 | 22.7% | 51.0% |
| 营业利润率 | -0.1% | -54.6% |
| 净利率 | -4.0% | — |
| 营收同比 | 7.1% | 17.1% |
| 净利润同比 | 58.1% | — |
| 每股收益（稀释后） | $-0.58 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CVEOZLAB
| Q4 25 | $161.6M | $127.1M | ||
| Q3 25 | $170.5M | $115.4M | ||
| Q2 25 | $162.7M | $109.1M | ||
| Q1 25 | $144.0M | $105.7M | ||
| Q4 24 | $151.0M | $108.5M | ||
| Q3 24 | $176.3M | $101.8M | ||
| Q2 24 | $188.7M | $100.1M | ||
| Q1 24 | $166.1M | $87.1M |
净利润CVEOZLAB
| Q4 25 | $-6.5M | — | ||
| Q3 25 | $-455.0K | $-36.0M | ||
| Q2 25 | $-3.3M | $-40.7M | ||
| Q1 25 | $-9.8M | $-48.4M | ||
| Q4 24 | $-15.4M | — | ||
| Q3 24 | $-5.1M | $-41.7M | ||
| Q2 24 | $8.2M | $-80.3M | ||
| Q1 24 | $-5.1M | $-53.5M |
毛利率CVEOZLAB
| Q4 25 | 22.7% | 51.0% | ||
| Q3 25 | 25.7% | 59.5% | ||
| Q2 25 | 25.3% | 60.6% | ||
| Q1 25 | 20.4% | 63.6% | ||
| Q4 24 | 18.6% | 61.5% | ||
| Q3 24 | 21.4% | 64.1% | ||
| Q2 24 | 25.4% | 64.9% | ||
| Q1 24 | 21.5% | 61.4% |
营业利润率CVEOZLAB
| Q4 25 | -0.1% | -54.6% | ||
| Q3 25 | 4.1% | -42.3% | ||
| Q2 25 | 1.7% | -50.3% | ||
| Q1 25 | -3.8% | -53.3% | ||
| Q4 24 | -6.7% | -62.6% | ||
| Q3 24 | 0.0% | -66.6% | ||
| Q2 24 | 6.9% | -76.0% | ||
| Q1 24 | -1.1% | -80.7% |
净利率CVEOZLAB
| Q4 25 | -4.0% | — | ||
| Q3 25 | -0.3% | -31.2% | ||
| Q2 25 | -2.0% | -37.3% | ||
| Q1 25 | -6.8% | -45.8% | ||
| Q4 24 | -10.2% | — | ||
| Q3 24 | -2.9% | -40.9% | ||
| Q2 24 | 4.4% | -80.2% | ||
| Q1 24 | -3.1% | -61.4% |
每股收益（稀释后）CVEOZLAB
| Q4 25 | $-0.58 | $-0.05 | ||
| Q3 25 | $-0.04 | $-0.03 | ||
| Q2 25 | $-0.25 | $-0.04 | ||
| Q1 25 | $-0.72 | $-0.04 | ||
| Q4 24 | $-1.04 | $-0.09 | ||
| Q3 24 | $-0.36 | $-0.04 | ||
| Q2 24 | $0.56 | $-0.08 | ||
| Q1 24 | $-0.35 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $14.4M | $689.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $174.4M | $715.5M |
| 总资产 | $477.4M | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CVEOZLAB
| Q4 25 | $14.4M | $689.6M | ||
| Q3 25 | $12.0M | $717.2M | ||
| Q2 25 | $14.6M | $732.2M | ||
| Q1 25 | $28.4M | $757.3M | ||
| Q4 24 | $5.2M | $779.7M | ||
| Q3 24 | $17.9M | $616.1M | ||
| Q2 24 | $7.4M | $630.0M | ||
| Q1 24 | $16.8M | $650.8M |
总债务CVEOZLAB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $43.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益CVEOZLAB
| Q4 25 | $174.4M | $715.5M | ||
| Q3 25 | $182.5M | $759.9M | ||
| Q2 25 | $209.4M | $791.7M | ||
| Q1 25 | $220.7M | $810.8M | ||
| Q4 24 | $236.4M | $840.9M | ||
| Q3 24 | $282.2M | $667.7M | ||
| Q2 24 | $297.4M | $704.2M | ||
| Q1 24 | $297.4M | $762.2M |
总资产CVEOZLAB
| Q4 25 | $477.4M | $1.2B | ||
| Q3 25 | $491.1M | $1.2B | ||
| Q2 25 | $508.8M | $1.2B | ||
| Q1 25 | $423.8M | $1.2B | ||
| Q4 24 | $405.1M | $1.2B | ||
| Q3 24 | $477.6M | $985.3M | ||
| Q2 24 | $483.2M | $987.4M | ||
| Q1 24 | $513.1M | $988.4M |
负债/权益比CVEOZLAB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.18× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $19.3M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $14.5M | $-26.7M |
| 自由现金流率自由现金流/营收 | 8.9% | -21.0% |
| 资本支出强度资本支出/营收 | 3.0% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $2.1M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流CVEOZLAB
| Q4 25 | $19.3M | $-26.0M | ||
| Q3 25 | $13.8M | $-32.0M | ||
| Q2 25 | $-2.3M | $-31.0M | ||
| Q1 25 | $-8.4M | $-61.7M | ||
| Q4 24 | $9.5M | $-55.8M | ||
| Q3 24 | $35.7M | $-26.8M | ||
| Q2 24 | $32.4M | $-42.2M | ||
| Q1 24 | $6.0M | $-90.1M |
自由现金流CVEOZLAB
| Q4 25 | $14.5M | $-26.7M | ||
| Q3 25 | $8.2M | $-35.0M | ||
| Q2 25 | $-6.8M | $-33.9M | ||
| Q1 25 | $-13.7M | $-63.2M | ||
| Q4 24 | $1.8M | $-58.4M | ||
| Q3 24 | $28.2M | $-28.2M | ||
| Q2 24 | $27.0M | $-42.9M | ||
| Q1 24 | $372.0K | $-91.1M |
自由现金流率CVEOZLAB
| Q4 25 | 8.9% | -21.0% | ||
| Q3 25 | 4.8% | -30.4% | ||
| Q2 25 | -4.2% | -31.1% | ||
| Q1 25 | -9.5% | -59.9% | ||
| Q4 24 | 1.2% | -53.8% | ||
| Q3 24 | 16.0% | -27.7% | ||
| Q2 24 | 14.3% | -42.9% | ||
| Q1 24 | 0.2% | -104.5% |
资本支出强度CVEOZLAB
| Q4 25 | 3.0% | 0.5% | ||
| Q3 25 | 3.3% | 2.6% | ||
| Q2 25 | 2.8% | 2.6% | ||
| Q1 25 | 3.7% | 1.5% | ||
| Q4 24 | 5.1% | 2.4% | ||
| Q3 24 | 4.2% | 1.3% | ||
| Q2 24 | 2.8% | 0.7% | ||
| Q1 24 | 3.4% | 1.1% |
现金转化率CVEOZLAB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 3.93× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CVEO
暂无分部数据
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
